Sunday, October 19, 2025 from 10:30 a.m. to 12:00 p.m. CDT at Northstar Ballroom A, 2nd Floor
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-25-142-L01-PActivity Type: A Knowledge-Based ActivityFirst, this session will provide a review of pertinent pathophysiology when defining heart failure in the pediatric patient with congenital heart disease. Secondly, the session will summarize recent data regarding novel agents such as SGLT2 and angiotensin receptor neprilysin inhibitors (ARNIs) in pediatric heart failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). Next, unique considerations for medical management of advanced heart failure in congenital heart disease and the role of ventricular assist devices (VADs) and required anticoagulation as a bridge to heart transplant will be reviewed. Lastly, the session will evaluate unique circumstances in caring for adults with congenital heart disease and heart failure (ACHD-HF) in the pediatric acute care setting. It is the purpose of this session to provide the pharmacist with the knowledge and tools to appropriately manage these high-risk cardiac patients.
Learning Objectives1. Describe cornerstone medication classes used in treatment of heart failure secondary to congenital heart disease.
2. Outline the role of novel agents (SGLT2 inhibitors and ARNI therapy) for treatment of pediatric heart failure secondary to congenital heart disease.
3. Explain the criteria for pediatric patients who would qualify for the implantation of ventricular assist devices (VADs).
4. Summarize anticoagulation considerations in pediatric patients with VADs who are awaiting heart transplant.
5. Discuss differences in outcomes when comparing heart failure in patients with and without underlying congenital heart disease.
6. Identify primary recommendations for the pediatric pharmacist managing adult congenital heart disease heart failure (ACHD-HF) exacerbations in the pediatric intensive care unit setting.
 | | Moderator: | Dominique G. Mark, Pharm.D., BCPPS | | Residency Program Director, PGY1 Pharmacy and PGY2 Pediatrics
Pediatric Clinical Pharmacist, Seattle Children's Hospital
Clinical Associate Professor, University of Washington School of Pharmacy | | View Biography |
|
Heart Smart: Unlocking the Potential of SGLT2 Inhibitors and ARNIs in Children with Congenital Heart Disease10:30 a.m. to 11:00 a.m. | | Speaker: | Bronwyn Crandall, Pharm.D., BCPPS | | Pediatric Clinical Pharmacy Specialist- Pediatric Cardiology, Cardiac Intensive Care, and Heart Transplant
C.S. Mott Children's Hospital
University of Michigan
Ann Arbor, Michigan | | View Biography |
|
|
Bridging the Gap: Ventricular Assist Devices and Anticoagulation in Pediatric Heart Failure11:00 a.m. to 11:30 a.m. | | Speaker: | Amy Lauren Haney, Pharm.D., BCPPS, BCPS | | Pediatric Clinical Pharmacy Specialist- Pediatric Cardiology and Cardiothoracic Surgery
Shawn Jenkins Children's Hospital
Medical University of South Carolina Children's Hospital
Charleston, South Carolina | | View Biography |
|
|
Growing Up Together: Pediatric Practitioners Tackling Adult Congenital Heart Disease11:30 a.m. to 12:00 p.m. | | Speaker: | Peter N. Johnson, Pharm.D., BCPPS | | Professor of Pharmacy Practice; OU College of Pharmacy; Oklahoma City, Oklahoma
PGY2 Pediatric Pharmacy Residency Director at OU College of Pharmacy and OU Health
Clinical Pharmacy Specialist in CICU at Oklahoma Children's Hospital at OU Health; Oklahoma City, Oklahoma | | View Biography |
|
|